CEO Statement to Shareholders
Emerging Growth Research Issues Flash Report on OSR Holdings, Reaffirms Buy-Emerging Rating and $10.00 Price Target
OSR Holdings to Present VXM01 Licensing Agreement at Emerging Growth Conference May 7, 2026
OSR Holdings Executes Definitive $815 Million Global License Agreement for VXM01 with BCM Europe
OSR Holdings Eliminates $2.02 Million Warrant Overhang with Premium-Priced Convertible Note
OSR Holdings to Update Investors at the Emerging Growth Conference on April 1, 2026
Emerging Growth Research Issues Flash Report on OSR Holdings, Inc., Reaffirms Buy-Emerging Rating and $10.00 Price Target
OSR Holdings Updates $815 Million VXM01 Licensing Deal Structure to Capture Value at Parent Level
Woori IO, an OSR Company, Signs NDA with Sinopharm to Explore China Commercial Opportunities
OSR Holdings, Inc. Granted 180-Day Nasdaq Extension; Reaffirms Strategic Momentum
Comparing OSR (NASDAQ:OSRH) and Currenc Group (NASDAQ:CURR)
Reviewing OSR (NASDAQ:OSRH) and Agassi Sports Entertainment (OTCMKTS:AASP)
CEO Statement to Shareholders
OSR Holdings Completes Woori IO Acquisition, Secures Long-Term Shareholder Alignment, and Reviews Strategic Combination of Medical Device Subsidiaries
Woori IO, an OSR Company, Highlights FDA Clarification on Non-Medical Wearables as a Catalyst for Accelerated Commercial Launch
Vaximm Appoints Sébastien Wieckowski, PhD, as Chief Scientific Officer to Advance Next-Generation Oral Immunotherapy Platform
Vaximm, an OSR Company, Receives Binding Term Sheet from BCM Europe for Global Exclusive License of VXM01 with $30M Upfront and Up to $815M in Milestones
Bellevue Life Sciences Acquisition (NASDAQ:BLAC) Stock Price Up 13.7% – Time to Buy?
Woori IO Shareholders Approve Share Exchange to Become Wholly-Owned Subsidiary of OSR Holdings
Presenting on Emerging Growth Conference 88 Day 1 on December 10; Register to live stream
Emerging Growth Research Issues Flash Report on OSR Holdings, Inc., Reaffirms Buy-Emerging Rating and $10.00 Price Target Following Major Licensing Agreement
Vaximm AG, an OSR Company, Updates Term Sheet with BCM Europe to Shorten Exclusivity Period to Three Months
OSR Holdings to Present at the Emerging Growth Conference on December 10, 2025
Vaximm AG, an OSR Company, Enters Term Sheet With BCM Europe for Potential VXM01 License with $20M Upfront and Up to $815M in Milestones
OSR Holdings Appoints Scientific Co-Founder Dr. Andreas Niethammer as Chief Executive Officer of Vaximm AG to Lead Next Phase of Immuno-Oncology Expansion
OSR Holdings Announces Woori IO's Noninvasive Glucose Monitor Demonstrates High Accuracy and Precision in Company-Sponsored Pilot Study
Emerging Growth Research Initiates Coverage on OSR Holdings, Inc. with a Buy-Emerging Rating and $10.00 Price Target
OSR Holdings Signs Definitive Agreement to Acquire Woori IO, a Pioneer in Noninvasive Glucose Monitoring with Potential to Transform Diabetes Care
OSR Holdings Receives Nasdaq Minimum Bid Price Deficiency Notice; Company Highlights Unusual Trading Activity
OSR Holdings to Host Virtual Investor Event Providing Key Corporate Updates and Strategic Direction on August 6, 2025
OSR Holdings Provides Transparency Update on Equity Financing Instruments
OSR Holdings Provides Strategic Update on Woori IO Term Sheet and Share Exchange Structure
OSR Holdings Enters into Term Sheet to Acquire Woori IO, a Pioneer in Noninvasive Glucose Monitoring Technology
OSR Holdings Appoints Dr. Andreas Niethammer as Chief Medical Officer of Vaximm AG, an OSR Company
OSR Holdings Announces Strategic Roadmap for Tokenization Under Reg D Framework in Partnership with BCM Europe AG
OSR Holdings, BCM Europe, and Taekwondo Cooperative Announce Strategic MOU to Launch Blockchain-Based OSRH Token
Darnatein to Present at 14th International BMP Conference Highlighting Advances in Regenerative Biologics
Darnatein, an OSR Company, Broadens Intellectual Property Protection for Innovative Osteoarthritis Treatment Technology
OSR Holdings, Inc. (NASDAQ: OSRH) Enters Into $80 Million Common Stock Purchase Agreement With White Lion GBM Innovation Fund, With An Eye Towards Leveraging Innovate GBM's Non-Profit Ecosystem to Accelerate Glioblastoma Therapies
Vaximm AG, an OSR Company, Announces Results from Phase 2a Trial of VXM01 and Avelumab Combination Therapy in Glioblastoma
OSR Holdings Appoints Dr. Constance Höfer as Chief Scientific Officer
OSR Holdings, Inc. and OSR Holdings Co., Ltd. Announce Completion of Business Combination
Bellevue Life Sciences Acquisition Corp. Announces Approval of Business Combination Proposal And Name Change to OSR Holdings, Inc.
Bellevue Life Sciences Acquisitions Corp. Reminds Stockholders to Vote in Favor of Extension at May 14, 2024 Stockholder Meeting
OSR Holdings and SillaJen have entered into a Memorandum of Understanding to collaboratively pursue the development of innovative therapeutics and enter the U.S. market
OSR Holdings Co., Ltd. Enters Into Business Combination Agreement with Bellevue Life Sciences Acquisition Corp.
Bellevue Life Sciences Acquisition Corp. and OSR Holdings Sign an Exclusive Letter of Intent for a Business Combination